University of Leicester
Browse
s12974-016-0770-9.pdf (654.99 kB)

Mannose-binding lectin-associated serine protease 2 (MASP-2) contributes to poor disease outcome in humans and mice with pneumococcal meningitis

Download (654.99 kB)
journal contribution
posted on 2017-08-15, 11:30 authored by E. Soemirien Kasanmoentalib, Mercedes Valls Seron, Bart Ferwerda, Michael W. Tanck, Aeilko H. Zwinderman, Frank Baas, Arie van der Ende, William J. Schwaeble, Matthijs C. Brouwer, Diederik van de Beek
Background: Pneumococcal meningitis is the most common and severe form of bacterial meningitis. Fatality rates are substantial, and long-term sequelae develop in about half of survivors. Disease outcome has been related to the severity of the pro-inflammatory response in the subarachnoid space. The complement system, which mediates key inflammatory processes, has been implicated as a modulator of pneumococcal meningitis disease severity in animal studies. Methods: We investigated mannose-binding lectin-associated serine protease (MASP-2) levels in cerebrospinal fluid (CSF) samples derived from the diagnostic lumbar puncture, which was available for 307 of 792 pneumococcal meningitis episodes included in our prospective nationwide cohort study (39%), and the association between these levels and clinical outcome. Subsequently, we studied the role of MASP-2 in our experimental pneumococcal meningitis mouse model using Masp2 −/− mice and evaluated the potential of adjuvant treatment with MASP-2-specific monoclonal antibodies in wild-type (WT) mice. Results: MASP-2 levels in cerebrospinal fluid of patients with bacterial meningitis were correlated with poor functional outcome. Consistent with these human data, Masp2-deficient mice with pneumococcal meningitis had lower cytokine levels and increased survival compared to WT mice. Adjuvant treatment with MASP-2-specific monoclonal antibodies led to reduced complement activation and decreased disease severity. Conclusions: MASP-2 contributes to poor disease outcome in human and mice with pneumococcal meningitis. MASP-2-specific monoclonal antibodies can be used to attenuate the inflammatory response in pneumococcal meningitis.

History

Citation

Journal of Neuroinflammation, 2017, 14:2

Version

  • VoR (Version of Record)

Published in

Journal of Neuroinflammation

Publisher

BioMed Central

issn

1742-2094

eissn

1742-2094

Acceptance date

2016-11-30

Copyright date

2016

Available date

2017-08-15

Publisher version

https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-016-0770-9

Notes

An erratum to this paper has been published at http://dx.doi.org/10.1186/s12974-017-0857-y / http://hdl.handle.net/2381/40189.

Language

en

Usage metrics

    University of Leicester Publications

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC